Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome

Completed

• Conditions: Influenza Vaccine; Cost-Benefit Analysis
• Interventions: Drug: Flu Vaccine

• Registration Number: NCT06304038
• Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Brief Summary

Flu vaccination, as well as being effective to prevent seasonal influenza, decreases staff illness and absenteeism and reduces costs resulting from loss of productivity. Despite the effectiveness of flu vaccination, the seasonal coverage among healthcare workers is usually low. The aim of this retrospective observational study is to analyze the vaccination coverage rate among all employees (healthcare workers and administrative staff) of a large teaching hospital in Rome during the 2017-2018 influenza season, to perform a cost-consequence analysis of influenza vaccination (by evaluating the absenteeism due to illness in the epidemic period), and to assess the impact of vaccination in terms of both costs and sick days.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-10-16
• Primary Completion: 2018-04-29
• Study Completion: 2019-11-14
• Study First Submitted: 2023-03-11
• Status Verified: 2024-03
• Study First Submitted QC: 2024-03-04
• Last Update Submitted: 2024-03-04
• Study First Posted: 2024-03-12
• Last Update Posted: 2024-03-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5483

Inclusion Criteria

• Healthcare workers at Fondazione Policlinico Universitario "A.Gemelli" IRCCS

Exclusion Criteria

• Healthcare workers not working at Fondazione Policlinico Universitario "A.Gemelli" IRCCS

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Vaccinated subjects	Flu Vaccine	Healthcare workers that received quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra in a single administration

Primary Outcome Measures

Name	Time	Method
Effectiveness of the quadrivalent vaccine	33 weeks	Effectiveness of the quadrivalent vaccine in reducing the number of working days lost due to influenza syndrome
Economic impact of the quadrivalent vaccine	33 weeks	Economic impact (for the company and society) of vaccination as part of a vaccination campaign on the healthcare workers of the teaching hospital.

Secondary Outcome Measures

Name	Time	Method
Expected economic savings for each one percentage point increase in vaccination coverage	33 weeks	Expected economic savings for each one percentage point increase in coverage on the health personnel of the teaching hospital
Non-economic incentives for healthcare personnel who decide to vaccinate	33 weeks	Non-economic incentives for healthcare personnel who decide to vaccinate, in view of the financial savings for the company, linked to increased vaccination coverage

Trial Locations

Locations (1)

Fondazione Policlinico Universitario "A.Gemelli" IRCCS; 🇮🇹 Rome, Italy